
|Videos|February 10, 2014
Toxicities Associated With Immunotherapies
Author(s)Harriet Kluger, MD
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the toxicities associated with immunotherapies.
Advertisement
Clinical Pearls
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the toxicities associated with immunotherapies.
- Toxicities associated with immunotherapies are completely different than what oncologists are accustomed to
- Immunotherapies are not necessarily less toxic than chemotherapies
- Pneumonitis and colitis are life-threatening
- Occasionally, toxicities associated with immunotherapies are difficult to recognize
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5



























